Al‐Ola Abdallah - Concepedia

Author

Al‐Ola Abdallah

University of Kansas Medical Center ORCID

Also Known As

A Abdallah, Al-Ola A Abdallah, Al-Ola A. Abdallah, Al-Ola Abdallah, Al-ola Abdallah, Al‐Ola Abdallah, Al–Ola Abdallah

284

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

University of Kansas Medical Center Medical University of South Carolina The University of Kansas Cancer Center Cleveland Clinic University of Maryland, Baltimore

About

Al‐Ola Abdallah is an author at University of Kansas Medical Center specializing in medicine, immunotherapy, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.3K
2	Health Sciences	5	5	217
3	Cellular Therapies	2	2	72
4	Public Health	1	1	130
5	Allergy	1	1	11

Al‐Ola Abdallah

Publications

Citations

H-Index

Page 1

	Year	Citations
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study Sagar Lonial, Hans C. Lee, Ashraf Badros, The Lancet Oncology Hematological MalignancyMedicinePathologyBelantamab MafodotinCancer Treatment	2019	772
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study Sagar Lonial, Hans C. Lee, Ashraf Badros, Cancer	2021	140
Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access Nausheen Ahmed, Moazzam Shahzad, Ernie Shippey, Transplantation and Cellular Therapy Health Care DisparityImmunologyHealth DisparitiesTravel TimeSocial Determinants Of Health	2022	130
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma Vânia Hungria, Paweł Robak, Marek Hus, New England Journal of Medicine	2024	127
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial Sagar Lonial, Rakesh Popat, Cyrille Hulin, The Lancet Haematology Hematological MalignancyMedicineHematologyImmunologyMyeloid Neoplasia	2022	83
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma Nico Gagelmann, Danai Dima, Maximilian Merz, Journal of Clinical Oncology	2024	70
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience Danai Dima, James A. Davis, Nausheen Ahmed, Transplantation and Cellular Therapy Hematological MalignancyOncologyReal-world ExperiencePathologyCancer Treatment	2023	68
Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma Al‐Ola Abdallah, Shebli Atrash, Zainab Shahid, Clinical Lymphoma Myeloma & Leukemia Hematological MalignancyNeuro-oncologyPathologyNeurologyMultiple Sclerosis	2013	61
Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial Ajay K. Nooka, Adam D. Cohen, Hans C. Lee, Cancer	2023	52
Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy James A. Davis, Douglas W. Sborov, William Wesson, Transplantation and Cellular Therapy Cell TherapyHealth SciencesDelayed Hematopoietic RecoveryStem Cell MobilizationStem Cell Transplantation	2023	42

Page 1